10Y UST4.83%+0.63%30Y MTG6.76%+0.75%SOFR3.64%VNQ$94.12-0.86%XLRE$43.05-0.83%FED FUNDS3.63%
Real Estate Trail
Institutional Press Wire
PR Newswire

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission

Via PR Newswire · September 10, 2026
Compiled by Real Estate Trail Editorial · September 10, 2026

Why this matters

Commercial real estate continues to digest a multi-year reset in cost of capital. Transaction velocity is below the 2019-2021 trend but improving, cap rates have stabilized across most stabilized property types, and the bid-ask gap has narrowed materially in the past two quarters. Sponsors with permanent capital and operating platforms have an advantage in the current execution environment. The next twelve months will continue to reward underwriting discipline and operational sophistication over balance-sheet aggression.

Editorial analysis · Real Estate Trail Editorial

Excerpt from PR Newswire:
TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for…
Read the full article at PR Newswire

External link. Real Estate Trail does not republish source content.

More from the wire